SunMax Biotechnology (4728) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 雙美

SunMax Biotechnology (4728) reported revenue of NT$190.3 million for Oct 2026, +18.2% year on year and -20.3% from the previous month. Revenue for Jan–Oct 2026 was NT$2.06 billion (+22.5% year on year).

Year-on-year revenue growth: 8 months in a row. →

In Oct 2026, it ranked No. 44 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$158.4 million24/10Nov 2024 NT$138.4 millionDec 2024 NT$149 millionJan 2025 NT$201.5 millionFeb 2025 NT$165.1 million25/02Mar 2025 NT$187.6 millionApr 2025 NT$155.9 millionMay 2025 NT$154.5 millionJun 2025 NT$149.8 million25/06Jul 2025 NT$148 millionAug 2025 NT$150 millionSep 2025 NT$205.7 millionOct 2025 NT$161 million25/10Nov 2025 NT$168.2 millionDec 2025 NT$179.1 millionJan 2026 NT$224.4 millionFeb 2026 NT$115.1 million26/02Mar 2026 NT$225.3 millionApr 2026 NT$202.1 millionMay 2026 NT$191.3 millionJun 2026 NT$224.8 million26/06Jul 2026 NT$221.5 millionAug 2026 NT$223.2 millionSep 2026 NT$238.8 millionOct 2026 NT$190.3 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$190.3 million+18.2%-20.3%
Sep 2026NT$238.8 million+16.1%+7.0%
Aug 2026NT$223.2 million+48.8%+0.8%
Jul 2026NT$221.5 million+49.7%-1.5%
Jun 2026NT$224.8 million+50.1%+17.5%
May 2026NT$191.3 million+23.8%-5.4%
Apr 2026NT$202.1 million+29.7%-10.3%
Mar 2026NT$225.3 million+20.1%+95.8%
Feb 2026NT$115.1 million-30.3%-48.7%
Jan 2026NT$224.4 million+11.4%+25.3%
Dec 2025NT$179.1 million+20.2%+6.5%
Nov 2025NT$168.2 million+21.6%+4.5%
Oct 2025NT$161 million+1.6%-21.8%
Sep 2025NT$205.7 million+18.9%+37.2%
Aug 2025NT$150 million+0.5%+1.4%
Jul 2025NT$148 million-7.7%-1.2%
Jun 2025NT$149.8 million-4.9%-3.0%
May 2025NT$154.5 million+4.4%-0.9%
Apr 2025NT$155.9 million-0.6%-16.9%
Mar 2025NT$187.6 million-0.8%+13.6%
Feb 2025NT$165.1 million+17.6%-18.1%
Jan 2025NT$201.5 million+105.2%+35.3%
Dec 2024NT$149 million+20.9%+7.6%
Nov 2024NT$138.4 million-5.4%-12.6%
Oct 2024NT$158.4 million+17.3%-8.4%

Jan–Oct 2026 cumulative: NT$2.06 billion (+22.5% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: SunMax Biotechnology vs PEC / SunMax Biotechnology vs Lotus Pharm / SunMax Biotechnology vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16